BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21556798)

  • 1. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells.
    Iwahashi S; Shimada M; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Mori H; Hanaoka J; Sugimoto K; Saito Y
    Int J Clin Oncol; 2011 Dec; 16(6):671-8. PubMed ID: 21556798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: a special reference to gene-expression microarray analysis.
    Iwahashi S; Shimada M; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Mori H; Hanaoka J; Saito Y
    Oncol Rep; 2011 Nov; 26(5):1057-62. PubMed ID: 21805043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valproic acid enhances the anti-tumor effect of pegylated interferon-α towards pancreatic cancer cell lines.
    Sugimoto K; Shimada M; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Iwahashi S
    Anticancer Res; 2014 Jul; 34(7):3403-9. PubMed ID: 24982347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX.
    Wang Y; Kuramitsu Y; Kitagawa T; Tokuda K; Baron B; Akada J; Nakamura K
    Target Oncol; 2015 Dec; 10(4):575-81. PubMed ID: 25940934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells.
    Wang JH; Lee EJ; Ji M; Park SM
    Oncol Rep; 2018 Jul; 40(1):346-354. PubMed ID: 29767267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibitory effects of pegylated IFN-alpha2b and 5-fluorouracil in combination on renal cell carcinoma cell lines in vitro and in vivo.
    Moriya F; Ogasawara S; Basaki Y; Akiba J; Kojiro S; Fukahori S; Ishizaki H; Nishida N; Matsuoka K; Kojiro M; Kuwano M; Yano H
    Int J Oncol; 2008 Oct; 33(4):647-55. PubMed ID: 18813777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.
    Haefner M; Bluethner T; Niederhagen M; Moebius C; Wittekind C; Mossner J; Caca K; Wiedmann M
    World J Gastroenterol; 2008 Jun; 14(23):3681-92. PubMed ID: 18595135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
    Samulitis BK; Pond KW; Pond E; Cress AE; Patel H; Wisner L; Patel C; Dorr RT; Landowski TH
    Cancer Biol Ther; 2015; 16(1):43-51. PubMed ID: 25485960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.
    Chun SG; Zhou W; Yee NS
    Cancer Biol Ther; 2009 Jul; 8(14):1328-39. PubMed ID: 19421011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha.
    Juengel E; Bhasin M; Libermann T; Barth S; Michaelis M; Cinatl J; Jones J; Hudak L; Jonas D; Blaheta RA
    World J Urol; 2011 Dec; 29(6):779-86. PubMed ID: 20640575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer.
    Liu YF; Luo D; Li X; Li ZQ; Yu X; Zhu HW
    Pancreas; 2021 Feb; 50(2):227-234. PubMed ID: 33565800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.
    Arnold NB; Arkus N; Gunn J; Korc M
    Clin Cancer Res; 2007 Jan; 13(1):18-26. PubMed ID: 17200334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.
    Sun L; Qian Q; Sun G; Mackey LV; Fuselier JA; Coy DH; Yu CY
    J Drug Target; 2016; 24(2):169-77. PubMed ID: 26211366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.
    Koga H; Selvendiran K; Sivakumar R; Yoshida T; Torimura T; Ueno T; Sata M
    Int J Oncol; 2012 Mar; 40(3):679-85. PubMed ID: 22020928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
    Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
    Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
    Zhao B; He T
    Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
    Iwahashi S; Ishibashi H; Utsunomiya T; Morine Y; Ochir TL; Hanaoka J; Mori H; Ikemoto T; Imura S; Shimada M
    J Med Invest; 2011 Feb; 58(1-2):106-9. PubMed ID: 21372494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-alpha2b induces p21cip1/waf1 degradation and cell proliferation in HeLa cells.
    Ota K; Matsumiya T; Sakuraba H; Imaizumi T; Yoshida H; Kawaguchi S; Fukuda S; Satoh K
    Cell Cycle; 2010 Jan; 9(1):131-9. PubMed ID: 20016288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pegylated interferon α2b on metastasis of hepatocellular carcinoma.
    Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T
    J Surg Res; 2012 Jan; 172(1):95-101. PubMed ID: 20851413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic activity of polyethylene glycol12000-interferon-alpha2b compared with interferon-alpha2b: gene modulatory and antigrowth effects in tumor cells.
    Vyas K; Brassard DL; DeLorenzo MM; Sun Y; Grace MJ; Borden EC; Leaman DW
    J Immunother; 2003; 26(3):202-11. PubMed ID: 12806274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.